Jackson Center, PA, October 25, 2021 – Halberd Corporation (OTC-PINK: HALB) announces the filing of a provisional patent application with the US Patent and Trademark Office covering their extracorporeal removal from the blood of patients of the various proteins, cytokines and antigens associated with obesity. Removal of these obesity-related target elements would reduce or eliminate ...
Jackson Center, PA, October 20, 2021 – Halberd Corporation’s (OTC-PINK: HALB) ongoing research into discovering treatments/cures for PTSD, Alzheimer’s Disease, and other neurodegenerative diseases has led to a potential breakthrough in the battle against obesity. Research has indicated inflammatory cytokines present in the Cerebral Spinal Fluid (CSF) of neurodegenerative disease patients are also found in ...
Abstract Aims/hypothesis A subset of obese individuals remains insulin sensitive by mechanisms as yet unclear. The hypothesis that maintenance of normal subcutaneous (SC) adipogenesis accounts, at least partially, for this protective phenotype and whether it can be abrogated by chronic exposure to IL-6 was investigated. Methods Adipose tissue biopsies were collected from insulin-sensitive (IS) and ...
Iria Nieto-Vazquez, Sonia Fernández-Veledo, David K. Krämer,Rocio Vila-Bedmar, Lucia Garcia-Guerra & Margarita Lorenzo Abstract Adipose tissue secretes proteins which may influence insulin sensitivity. Among them, tumour necrosis factor (TNF)-alpha has been proposed as a link between obesity and insulin resistance because TNF-alpha is overexpressed in adipose tissue from obese animals and humans, and obese mice ...
SOURCE: https://news.mit.edu/2016/fat-fighting-nanoparticles-obesity-0502 "Researchers at MIT and Brigham and Women’s Hospital have developed nanoparticles that can deliver antiobesity drugs directly to fat tissue. Overweight mice treated with these nanoparticles lost 10 percent of their body weight over 25 days, without showing any negative side effects. The drugs work by transforming white adipose tissue, which is ...
Abstract Objective: We undertook this study to determine the relationship among -174G>C and 598G>A polymorphisms in the promoter region of interleukin-6, obesity, and metabolic abnormalities in subjects from central Mexico. Methods: Included in the study were 150 subjects who were not first-degree relatives of patients with diabetes and 106 blood samples from the general population. ...
Abstract Objective: To investigate the relationship between alpha 1-antitrypsin (A1AT), adiponectin, leptin, blood glucose, and insulin protein levels in human serum and obesity. Methods: Forty-eight subjects with normal blood glucose levels and average age of 32.4+/-5.1 years were enrolled in this study. The study took place in the Reproductive Center, The Second Hospital of Jilin University, Changchun, ...
GTX and Halberd will begin collaborating on developing and testing treatments for Alzheimer’s Disease/PTSD and other neurological diseases and GTX will begin marketing Halberd’s VitaShieldMaxTM Immune Support through their online ecommerce platform. Jackson Center, PA, October 12, 2021 – Halberd Corporation (OTC-PINK: HALB) and GTX Corp (OTC-PINK: GTXO) have agreed to work together on various ...
Q3-21 Accomplishments and Q4 Plans Jackson Center, PA, October 7, 2021 Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC-PINK: HALB) This past quarter, Halberd has made some very significant and unparalleled achievements developing treatments for neurodegenerative diseases, such as PTSD/ CTE (Post Traumatic Stress Disorder/Chronic Traumatic Encephalopathy), Alzheimer’s Disease, Parkinson’s Disease, etc. As ...
Jackson Center, PA, October 5, 2021 – Halberd Corporation (OTC-PINK: "HALB") announced that its nutraceutical immune support product, VitaShieldMaxTM, is now available through Amazon, in addition to its availability through Halberd’s website at www.vitashieldmax.com. William A. Hartman, Halberd's Chairman, President & CEO, stated, “We are pleased that our product will now also be available through ...